Geographic adoption continues in Europe, Latin America and Asia

September 16, 2014 09:39 AM Eastern Daylight Time

DELRAY BEACH, Fla.–(BUSINESS WIRE)–VeriTeQ Corporation (“VeriTeQ”) (OTC Markets: VTEQ), a provider of implantable medical device identification and radiation dose measurement technologies, announced today that more than 1,000 women worldwide have now received Motiva Implant Matrix® breast implants with VeriTeQ’s Q Inside Safety Technology™. Motiva Implant Matrix® breast implants, manufactured by Establishment Labs S.A. (“EL”), featuring VeriTeQ’s Q Inside Safety Technology™ can be safely and accurately identified from outside of the body in a physician’s office.

VeriTeQ’s FDA cleared Q Inside Safety Technology™ acts as an electronic serial number in breast implants and other implantable and reusable medical devices to provide physicians and patients access to secure online databases to retrieve device-specific data, such as serial number, manufacturer name, date of manufacture, lot number, volume, size, and other data from the medical device manufacturer. Q Inside Safety Technology™ may also provide an extra level of protection to the patient in the event of a recall or other safety event.

EL’s Motiva Implant Matrix® Ergonomix™, VelvetSurface® PLUS, and SilkSurface® PLUS, all with VeriTeQ’s Q Inside Safety Technology, have received CE Mark approval.

“This is an important milestone for Motiva and a clear signal to the industry that women value innovation and safety in long-term implantable devices,” said Juan Jose Chacon-Quiros, Chief Executive Officer of EL.

“We are very proud of the work we are doing with our partner Establishment Labs to reach this significant milestone for our medical device identification business,” said Scott R. Silverman, VeriTeQ’s Chairman and Chief Executive Officer. “EL continues to see increased demand for its best-in-class breast implants as both physicians and patients request enhanced identification and other advanced technology options for their medical devices.”

About VeriTeQ

VeriTeQ develops innovative, proprietary RFID technologies for implantable medical device identification, and dosimeter technologies for use in radiation therapy treatment. VeriTeQ offers the world’s first FDA cleared RFID microchip technology that can be used to identify implantable medical devices, in vivo, on demand, at the point of care. VeriTeQ’s dosimeters provide patient safety mechanisms while measuring and recording the dose of radiation delivered to a patient in real time. For more information on VeriTeQ, please visit www.veriteqcorp.com.

About EL

Establishment Labs is a privately held, global breast, body and facial aesthetic company with offices in Florida, Costa Rica and Belgium, that designs, develops, manufactures and markets an innovative product portfolio consisting of advanced silicone-filled breast (www.motivaimplants.com) and body shaping implants. Utilizing only the highest quality of medical grade silicones, the CE-marked Motiva Implant Matrix® line is rigorously scrutinized by professional Quality Engineers throughout the entire manufacturing process. All its products are manufactured in full compliance with ISO and EU requirements, and are certified under the Medical Device Directive 93/42/EEC. For more information on EL, please visit www.establishmentlabs.com.

Statements in this press release about our future expectations, including the likelihood that Q Inside Safety Technology may also provide an extra level of protection to the patient in the event of a recall or other safety event; constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, VeriTeQ’s ability to raise capital; as well as other risks. Additional information about these and other factors may be described in VeriTeQ’s Form 10-K, filed on April 15, 2014, and Forms 10-Q, filed on August 20, 2014, May 14, 2014, and November 14, 2013, and future filings with the Securities and Exchange Commission The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

Contacts

VeriTeQ
Allison Tomek, 561-846-7003
atomek@veriteqcorp.com